CML exposure markedly elevated the p-PERK/PERK and p-eIF2α/eIF2α ratios by 4.1-fold and 3.6-fold, respectively (p < 0.001 vs. control; Figure 4A). The gene discussed is EIF2A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.